专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010090857A2 METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS 审中-公开
标题翻译：扩增丙型肝炎病毒核酸的方法
公开(公告)号：WO2010090857A2
公开(公告)日：2010-08-12
申请号：PCT/US2010/021589
申请日：2010-01-21
申请人： VERTEX PHARMACEUTICALS INCORPORATED , KWONG, Ann, D. , FRANTZ, James, Daniel , BARTELS, Douglas, J. , LIN, Chao , SHAMES, Benjamin , SEEPERSAUD, Sheila , LIPPKE, Judith, A. , KIEFFER, Tara, L. , ZHOU, Yi , ZHANG, Eileen, Z. , SULLIVAN, James, C.
发明人： KWONG, Ann, D. , FRANTZ, James, Daniel , BARTELS, Douglas, J. , LIN, Chao , SHAMES, Benjamin , SEEPERSAUD, Sheila , LIPPKE, Judith, A. , KIEFFER, Tara, L. , ZHOU, Yi , ZHANG, Eileen, Z. , SULLIVAN, James, C.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/707 , C12Q1/6883
摘要： A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.
摘要翻译：扩增HCV感染样品中的HCV核酸的方法包括通过两阶段PCR扩增与来自样品的HCV RNA基因组互补的DNA模板片段，其中a 第一阶段PCR使用第一外部引物和第二外部引物，并且第二阶段PCR使用第一内部引物和第二内部引物。第一外部引物的核苷酸序列包含如SEQ ID NO：2所示的核苷酸序列; 或SEQ ID NO：9的核苷酸序列，其中任选地1,2或3个核苷酸是除SEQ ID NO：9的核苷酸以外的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO：3或4所示的核苷酸序列; 或如SEQ ID NO：10或11所示的核苷酸序列，其中任选地1,2或3个核苷酸是与SEQ ID NO：10和11的那些核苷酸不同的核苷酸。第一内部引物的核苷酸序列包含核苷酸序列如SEQ ID NO：5所示; 或SEQ ID NO：12，其中任选地1,2或3个核苷酸是不同于SEQ ID NO：12的核苷酸。第二内部引物的核苷酸序列包含如SEQ ID NO：6或7所示的核苷酸序列 ; 或如SEQ ID NO：13或14所示的核苷酸序列，其中任选地1,2或3个核苷酸是不同于SEQ ID NO：13和14的那些核苷酸。

2. 发明申请

WO2010025380A3 ANALYSIS OF HCV GENOTYPES 审中-公开
标题翻译： HCV基因型分析
公开(公告)号：WO2010025380A3
公开(公告)日：2010-08-05
申请号：PCT/US2009055385
申请日：2009-08-28
申请人： VERTEX PHARMA , BARTELS DOUGLAS , KWONG ANN , KIEFFER TARA
发明人： BARTELS DOUGLAS , KWONG ANN , KIEFFER TARA
IPC分类号： A61K38/21 , A61K31/00 , A61P31/12 , G01N33/50
CPC分类号： A61K45/06 , A61K31/00 , A61K38/21 , A61K38/212 , C12Q1/6883 , C12Q1/707 , C12Q2600/106 , C12Q2600/156 , G01N33/5767 , G01N2333/18 , A61K2300/00
摘要： A method for predicting response of a patient infected with HCV-Ia to interferon treatment.
摘要翻译：预测感染HCV-1a的患者对干扰素治疗的反应的方法。

3. 发明申请

WO2007059221A9 HEPATITIS C VIRUS VARIANTS 审中-公开
标题翻译：丙型肝炎病毒变种
公开(公告)号：WO2007059221A9
公开(公告)日：2007-08-23
申请号：PCT/US2006044363
申请日：2006-11-13
申请人： VERTEX PHARMA , LIN CHAO , KIEFFER TARA , SARRAZIN CHRISTOPH , KWONG ANN
发明人： LIN CHAO , KIEFFER TARA , SARRAZIN CHRISTOPH , KWONG ANN
CPC分类号： C07K14/005 , C12N2770/24222 , C12Q1/34 , G01N33/56983 , G01N2500/00
摘要： The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
摘要翻译：本发明涉及HCV变体，特别是对诸如VX-950的蛋白酶抑制剂具有抗性的变体。还提供了与HCV变体有关的方法和组合物。进一步提供了从患者分离，鉴定和表征多种病毒变体的方法。

4. 发明申请

WO2007059221A3 HEPATITIS C VIRUS VARIANTS 审中-公开
公开(公告)号：WO2007059221A3
公开(公告)日：2007-05-24
申请号：PCT/US2006/044363
申请日：2006-11-13
申请人： VERTEX PHARMACEUTICALS, INC , LIN, Chao , KIEFFER, Tara , SARRAZIN, Christoph , KWONG, Ann
发明人： LIN, Chao , KIEFFER, Tara , SARRAZIN, Christoph , KWONG, Ann
IPC分类号： C07K14/18
摘要： The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

5. 发明申请

WO2004044037A1 A SYNTHETIC LATEX COMPOSITION 审中-公开
标题翻译：合成LATEX组合物
公开(公告)号：WO2004044037A1
公开(公告)日：2004-05-27
申请号：PCT/AU2003/001350
申请日：2003-10-13
申请人： WRP ASIA PACIFIC SDN. BHD. , IP ORGANISERS PTY LTD , LEW, Kwong, Ann , BARCLAY, Leslie, Martin , WONG, Ah, Kiew , JAYARAMAN, Sarala, Devi
发明人： LEW, Kwong, Ann , BARCLAY, Leslie, Martin , WONG, Ah, Kiew , JAYARAMAN, Sarala, Devi
IPC分类号： C08J3/26
CPC分类号： C08J3/26 , A41D19/0055 , A61B42/00 , C08C19/36 , C08J2313/00 , C08K3/22 , C08L13/02
摘要： There is provided a synthetic latex compound composition for producing non-staining dipped rubber articles such as a non-staining glove, condom, finger cot and balloon, comprising of a synthetic carboxylated acrylonitrile butadiene rubber or a synthetic carboxylated butadiene co-polymer rubber, free from any sulphur or sulphur containing chemicals or accelerators. The sole cross-linking system comprising only of polyvalent metal chemicals, rendering the rubber articles, free from copper staining or staining with other heavy metals, as well as being free from Type I and Type IV Allergens.
摘要翻译：提供了一种合成胶乳化合物组合物，用于生产无染色的浸渍橡胶制品，如无污染的手套，避孕套，手指和气球，包括合成的羧化丙烯腈丁二烯橡胶或合成的羧化的丁二烯共聚物橡胶，来自任何含硫或含硫化学物质或加速剂。仅包含多价金属化学品的唯一交联体系，使橡胶制品不含铜污染或与其它重金属染色，并且不含I型和IV型过敏原。

6. 发明申请

WO02061149A3 A QUANTITATIVE ASSAY FOR NUCLEIC ACIDS 审中-公开
标题翻译：核酸的定量测定
公开(公告)号：WO02061149A3
公开(公告)日：2003-07-03
申请号：PCT/US0202653
申请日：2002-01-30
申请人： VERTEX PHARMA , LIN CHAO , KWONG ANN
发明人： LIN CHAO , KWONG ANN
IPC分类号： C12Q1/68 , C12Q1/70
CPC分类号： C12Q1/703 , C12Q1/6851 , C12Q2561/101 , C12Q2545/101
摘要： The present invention provides a method of accurately assaying the amount of nucleic acids in a biological source. According to another embodiment, the present invention provides a method of accurately assaying HCV in a biological source. The present invention also provides a method fo simultaneously screening the effect of a plurality of compounds on the replication of a whole or part of a genome of a biological source. The present invention provides a method of simultaneously screening the effect of a plurality of compounds on the replication of the whole or part of the HCV genome in a biological source.
摘要翻译：本发明提供了准确测定生物来源中核酸量的方法。根据另一个实施方案，本发明提供了在生物来源中准确测定HCV的方法。本发明还提供同时筛选多种化合物对生物来源的全部或部分基因组的复制的影响的方法。本发明提供了同时筛选多种化合物对生物来源中全部或部分HCV基因组复制的影响的方法。

7. 发明申请

WO2007059221A2 HEPATITIS C VIRUS VARIANTS 审中-公开
公开(公告)号：WO2007059221A2
公开(公告)日：2007-05-24
申请号：PCT/US2006044363
申请日：2006-11-13
申请人： VERTEX PHARMA , LIN CHAO , KIEFFER TARA , SARRAZIN CHRISTOPH , KWONG ANN
发明人： LIN CHAO , KIEFFER TARA , SARRAZIN CHRISTOPH , KWONG ANN
CPC分类号： C07K14/005 , C12N2770/24222 , C12Q1/34 , G01N33/56983 , G01N2500/00
摘要： The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
摘要翻译：本发明涉及HCV变体，特别是对蛋白酶抑制剂如VX-950具有抗性的变体。还提供了与HCV变体相关的方法和组合物。还提供了从患者分离，鉴定和表征多种病毒变体的方法。

8. 发明申请

WO02077206A9 COMPOSITIONA AND METHODS USEFUL FOR HCV INFECTION 审中-公开
标题翻译：用于HCV感染的组合物和方法
公开(公告)号：WO02077206A9
公开(公告)日：2004-02-19
申请号：PCT/US0209685
申请日：2002-03-27
申请人： VERTEX PHARMA , KWONG ANN , BYRN RANDAL , REID LOLA M
发明人： KWONG ANN , BYRN RANDAL , REID LOLA M
IPC分类号： G01N33/50 , C12N5/071 , C12N7/00 , C12N15/09 , C12Q1/68 , G01N33/15 , C12N5/00 , C12N15/85 , C12N15/86 , C12Q1/70
CPC分类号： C12Q1/70 , C12N5/0031 , C12N5/0037 , C12N5/067 , C12N7/00 , C12N2500/20 , C12N2500/25 , C12N2500/36 , C12N2500/46 , C12N2500/90 , C12N2501/11 , C12N2501/12 , C12N2501/18 , C12N2501/335 , C12N2501/375 , C12N2501/39 , C12N2502/11 , C12N2770/24011
摘要： The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for injecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
摘要翻译：本发明提供了包含能够在HCV感染后有效产生HCV的细胞的组合物，用于培养细胞的组合物，用于制备组合物的方法和用HCV注射组合物中的细胞的方法。本发明还提供了用于测定HCV产生的方法以及评价影响HCV产生的化合物的方法。

9. 发明申请

WO0015210A2 METHODS OF TREATING VIRAL DISEASE 审中-公开
标题翻译：治疗病毒的方法
公开(公告)号：WO0015210A2
公开(公告)日：2000-03-23
申请号：PCT/US9921003
申请日：1999-09-14
申请人： VERTEX PHARMA , TUNG ROGER , KWONG ANN
发明人： TUNG ROGER , KWONG ANN
IPC分类号： C07D307/88 , A61K31/343 , A61K31/365 , A61K31/5377 , A61K38/21 , A61P31/12 , A61P31/20 , A61K31/00
CPC分类号： A61K31/365 , A61K38/212 , A61K2300/00
摘要： The invention relates to methods of treating viral diseases caused by viruses of the family Flaviviridae, or by a virus which targets the mammalian liver as a main repository for viral replication. The methods of this invention involve the use of mycophenolic acid or its derivatives, particularly mycophenolate mofetil alone, or in combination with other anti-viral agents. The methods of this invention are particularly useful in treating hepatitis B virus, hepatitis C virus, and dengue virus viral infections.
摘要翻译：本发明涉及治疗由黄病毒科病毒引起的病毒性疾病的方法，或涉及以哺乳动物肝脏为靶向病毒复制主要病毒的病毒。本发明的方法涉及霉酚酸或其衍生物，特别是单独的霉酚酸酯或与其它抗病毒剂组合使用。本发明的方法特别可用于治疗乙型肝炎病毒，丙型肝炎病毒和登革热病毒病毒感染。

10. 发明申请

WO2011156545A1 VIRAL DYNAMIC MODEL FOR HCV COMBINATION THERAPY 审中-公开
标题翻译： HCV组合治疗的病毒动态模型
公开(公告)号：WO2011156545A1
公开(公告)日：2011-12-15
申请号：PCT/US2011/039712
申请日：2011-06-09
申请人： VERTEX PHARMACEUTICALS INCORPORATED , ADIWIJAYA, Bambang, Senoaji , CARON, Paul, R. , GARG, Varun , KIEFFER, Tara, Lynn , KWONG, Ann Dak-Yee , KAUFFMAN, Robert, S.
发明人： ADIWIJAYA, Bambang, Senoaji , CARON, Paul, R. , GARG, Varun , KIEFFER, Tara, Lynn , KWONG, Ann Dak-Yee , KAUFFMAN, Robert, S.
IPC分类号： G01N33/576 , G06F19/00
CPC分类号： G01N33/5767
摘要： A model of HCV dynamics to quantify responses in subjects dosed with a combination of PR and a protease inhibitor is provided. The model quantitatively predicts clinical outcomes of alternative durations of the protease inhibitor and PR, and these predictions correspond well to the empirically observed outcomes in clinical trials. This model accounts for multiple HCV variants with reduced replicative fitness and susceptibility to protease inhibitors, and examines how these properties of the variants contribute to the HCV dynamics in subjects dosed with the triple combination therapy. Furthermore, the model provides insight into the mechanisms of how protease inhibitor-based regimens increase the SVR rate and reduce total duration of treatment, and predicts that the protease inhibitor-mediated reduction in the overall fitness of the HCV quasispecies, along with potential synergy of protease inhibitors and PR, may enable previous PR nonresponders to achieve SVR on T/PR treatment.
摘要翻译：提供了HCV动力学模型，用于定量给予PR和蛋白酶抑制剂组合的受试者的反应。该模型定量预测了蛋白酶抑制剂和PR的替代持续时间的临床结果，这些预测与临床试验中经验观察到的结果很好地吻合。该模型考虑了多种HCV变异体，其具有降低的复制适应性和对蛋白酶抑制剂的易感性，并且检查这些变体的这些性质如何有助于用三联组合治疗的受试者的HCV动态。此外，该模型提供了对蛋白酶抑制剂方案如何增加SVR率和减少治疗总持续时间的机制的了解，并预测蛋白酶抑制剂介导的HCV准种总体适应性的降低以及潜在的协同作用蛋白酶抑制剂和PR，可以使先前的PR无应答者在T / PR治疗上实现SVR。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式